MK-677

MK-677 (ibutamoren) is a growth hormone secretagogue that has been investigated in several clinical contexts, though its current therapeutic applications remain limited and primarily investigational.

Growth Hormone Deficiency

Clinical trials have explored MK-677's potential in treating growth hormone deficiency in pediatric populations. A Phase 3 study examining LUM-201 (which includes MK-677 components) in children with growth hormone deficiency is currently recruiting participants, indicating ongoing interest in this application.

End-Stage Renal Disease (ESRD)

One completed trial investigated MK-677's effects on IGF-1 levels in patients with end-stage renal disease, exploring its potential role in managing growth hormone-related complications in this population.

Fibromyalgia

A Phase 2 clinical trial examined the efficacy and safety of oral MK-677 for fibromyalgia treatment, representing an investigation into pain and symptom management applications.

Alzheimer's Disease

MK-677 was studied in a Phase 2 trial for Alzheimer's disease treatment, though this application appears to have limited current development.

Nonalcoholic Fatty Liver Disease (NAFLD)

A completed Phase 2 trial investigated MK-677's impact on nonalcoholic fatty liver disease, exploring metabolic applications.

Recreational and Performance Enhancement Use

The available literature reveals concerning patterns of off-label recreational use. Case reports document serious adverse effects including:

• Spontaneous splenic rupture in a patient using performance-enhancing compounds
• Hepatotoxicity directly attributed to MK-677 use
• Reversible gynecomastia and hypogonadism from commercial supplement use
• Effects on body composition and hormonal markers in recreational users

Current Clinical Status

The evidence suggests MK-677 remains primarily in investigational phases for most applications, with ongoing research in pediatric growth disorders. The compound's detection in doping control studies indicates regulatory concerns about its use in competitive athletics.

Important Note: The available clinical evidence is limited, and most therapeutic applications remain investigational. Case reports highlight potential serious adverse effects with off-label use. This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for any medical decisions.